<DOC>
	<DOCNO>NCT01123811</DOCNO>
	<brief_summary>Based current promising result irinotecan cetuximab patient recurrent metastatic colorectal cancer , excellent result Irinotecan 5-FU gastric cancer , present clinical study evaluate overall response rate , time progression overall survival combine treatment cetuximab irinotecan 5-FU patient esophagogastric cancer urgently need .</brief_summary>
	<brief_title>Efficacy Cetuximab Combination With Irinotecan 5- FU/FA Treatment Metastatic Gastric Cancer</brief_title>
	<detailed_description>Cetuximab analyse biological marker</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed date informed consent start specific protocol procedure ; Histologically prove gastric adenocarcinoma include adenocarcinoma esophagogastric junction Barrett carcinoma ( adenocarcinoma low oesophagus ) ; Measurable metastatic disease accord RECIST criterion . If locally recurrent disease , must associate least one measurable lymph node ( &gt; 20 mm CT scan &gt; 10 mm spiral CT ) ; Age : 1875 year ; ECOG Performance Status 02 Life expectancy &gt; 12 week ; Adequate hematological , hepatic renal function : ANC ≥ 1.5 × 109/L , platelet ≥ 100 × 109/L ; hemoglobin ≥ 10g/dl ; creatinine ≤ 2 x UNL ; total bilirubin ≤ 3 x UNL , ASAT ( SGOT ) ALAT ( SGPT ) ≤ 3 × UNL ; case liver metastasis : total bilirubin ≤ 5 x UNL , ASAT ( SGOT ) ALAT ( SGPT ) ≤ 5 × UNL ; At least 4 week surgery ; Recovery side effect prior therapy ; Able comply schedule assessment management toxicity . If childbearing potential , willingness use effective contraceptive method study duration 2 month postdosing . Other tumor type adenocarcinoma ( e.g. , leiomyosarcoma , lymphoma ) second cancer except patient squamous basal cell carcinoma skin carcinoma situ cervix effectively treat . Patients curatively treat disease free least 5 year discuss sponsor inclusion ; Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol ; Any prior palliative chemotherapy , adjuvant ( and/or neoadjuvant ) chemotherapy radiotherapy ; Concurrent treatment anticancer therapy ; Patients know brain leptomeningeal metastasis ; Hypercalcemia control bisphosphonates ; Bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection ( &gt; hemicolectomy extensive small intestine resection chronic diarrhea ) , Crohn 's disease , ulcerative colitis ; Other serious illness medical condition : Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry ; congestive heart failure NYHA grade 3 4 ; Current history chronic diarrhea ; History significant neurologic psychiatric disorder include dementia seizure ; Active uncontrolled infection ; Active disseminate intravascular coagulation ; Other serious underlie medical condition could impair ability patient participate study ; Known deficit DPD Contraindications use atropine ; Concomitant within 4week period administration experimental drug investigation ; Pregnant lactate woman ; Previous exposure monoclonal antibody , signal transduction inhibitor EGFR pathway target therapy ; Known allergic/hypersensitivity reaction component treatment ; Known drug abuse/alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>esophagogastric junction cancer</keyword>
</DOC>